ArticleJournal of clinical periodontology2026
From the Proteome to Therapeutics: A Multi-Database Approach to Drug Discovery in Periodontitis-An Exploratory Pilot Study.
Article in Journal of clinical periodontology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
introductionThis explanatory pilot study presents a workflow to identify approved drugs, which could be repurposed for periodontitis therapy using salivary proteomics combined with drug-target database screening.
methodsProteomic analyses of saliva using LC-MS/MS were conducted in two independent settings: a cohort (sub-study I, N = 187) and case-control (sub-study II, N = 72). Statistical analyses were performed using both stringent and lenient criteria. Under the stringent (lenient) criteria, proteins were considered potential targets if they showed a q-value < 0.05 (< 0.1) in the cohort study and a p-value < 0.05 together with an absolute fold change > 1.5 (1.3) in the case-control study. Four databases were searched to assess whether these proteins are known targets of approved drugs.
resultsIn the stringent (lenient) analysis one (26) proteins were associated with periodontitis in both studies, of which one (nine) were reported drug targets and one (seven) of those were potential drug targets in periodontitis. Target screening in databases identified 3/11 approved drugs, with eight of them having potential for repurposing for periodontal treatment. Several of these drugs (e.g., HDAC inhibitors, sivelestat, compstatin derivatives, auranofin, artenimol and bortezomib) have already shown efficacy in preclinical models of periodontal host modulation.
conclusionThis exploratory pilot study provided insights into potential therapeutic targets and potential drugs for periodontitis treatment. This workflow may help to identify approved drugs that could be repurposed for periodontal treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.